

\$1614



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Steven C. Quay

Serial No.: 09/678,591

Group Art Unit: 1614

Filing Date: October 3, 2000

Examiner: Dwayne C. Jones

For: LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND
PREVENTION OF BREAST CANCER AND PSYCHIATRIC DISORDERSDATE OF DEPOSIT: March 18, 2002I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE
INDICATED ABOVE AND IS ADDRESSED TO THE
ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, DC 20231.TYPED NAME: JEFFREY J. KING
REGISTRATION NO. 38,515Box ☐ NON-FEE
☐ AFCommissioner for Patents
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- ☐ A Preliminary Amendment.
- ☒ An Amendment Responsive to the Office Action Dated December 18, 2001.
- ☐ An Amendment Supplemental to the Paper filed _____.
- ☐ Other: _____.
- ☒ Applicant(s) has previously claimed small entity status under 37 CFR §1.27.

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

☐ Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR §1.27 as:

- ☐ an Independent Inventor
- ☐ a Small Business Concern
- ☐ a Nonprofit Organization

☐ This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.

☐ Substitute Pages _____ of the Specification are enclosed.

☐ An Abstract is enclosed.

☐ _____ Sheets of Proposed Corrected Drawings are enclosed.

☐ A Certified Copy of each of the following applications:
is enclosed.

☐ An Associate Power of Attorney is enclosed.

☐ Information Disclosure Statement.

☐ Attached Form 1449.

☐ A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.

☐ Appended Material as follows: _____.

☒ Other Material as follows: Copies of the March 26, 2001 Information Disclosure Statement, Transmittal Form, Form PTO-1449, and return receipt postcard.

FEE CALCULATION

☐ No Additional Fee is Due.


	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	SMALL ENTITY		NOT SMALL ENTITY	
				RATE	FEE	RATE	FEE
TOTAL CLAIMS	50	38 (20 MINIMUM)	12	\$9 EACH	\$108.00	\$18 EACH	\$
INDEP. CLAIMS	6	5 (3 MINIMUM)	1	\$42 EACH	\$42.00	\$84 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$140	\$	\$280	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$200	\$	\$400	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$460	\$	\$920	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$150.00		\$

- ☒ A Check is Enclosed in the Foregoing Amount Due.
- ☐ Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of __ to and through __ comprising an extension of the shortened statutory period of __ month(s).
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.
- ☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

- ☐ The Foregoing Amount Due for Filing this Paper.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- ☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.


Date: March 18, 2002



Jeffrey J. King
Registration No. 38,515

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439 © 2001 WW

DOCKET NO.: ATC 0035



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

Re Application of:

Steven C. Quay

Serial No.: 09/678,591

Group Art Unit: 1614

Filing Date: October 3, 2000

Examiner: Dwayne C. Jones

For: LONG-ACTING OXYTOCIN ANALOGUES FOR THE TREATMENT AND
PREVENTION OF BREAST CANCER AND PSYCHIATRIC DISORDERS

DATE OF DEPOSIT: March 18 2002
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE
PREPAID ON THE DATE INDICATED ABOVE
AND IS ADDRESSED TO THE COMMISSIONER
FOR PATENTS AND TRADEMARKS,
WASHINGTON, DC 20231.

TYPED NAME: Jeffrey J. King
REGISTRATION NO.: 38,515

Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT

In response to the Office Action dated December 18, 2001, entry and
consideration of the following amendments and remarks is earnestly requested.

IN THE CLAIMS:

Please add new claims 39-50 as follows:

A¹

--39. (New) A method for treatment of breast cancer in a mammalian patient
comprising administering to said patient a therapeutically effective amount of one or
more compound(s) selected from the group consisting of carbetocin and other long-acting
oxytocin analogues in a pharmaceutically acceptable carrier sufficient to inhibit growth
of breast cancer in said patient.

40. (New) The method of claim 39, wherein said one or more oxytocin
analogue(s) comprises carbetocin.